AR095601A1 - Diazilhidrazinas que contienen boro - Google Patents

Diazilhidrazinas que contienen boro

Info

Publication number
AR095601A1
AR095601A1 ARP140101226A ARP140101226A AR095601A1 AR 095601 A1 AR095601 A1 AR 095601A1 AR P140101226 A ARP140101226 A AR P140101226A AR P140101226 A ARP140101226 A AR P140101226A AR 095601 A1 AR095601 A1 AR 095601A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
alkyl
hydrogen
hydroxy
Prior art date
Application number
ARP140101226A
Other languages
English (en)
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of AR095601A1 publication Critical patent/AR095601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N55/00Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
    • A01N55/08Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing boron
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Es útil para aplicaciones tales como la terapia génica, el tratamiento de enfermedades, la producción a gran escala de proteínas y anticuerpos, los ensayos de cribado basados en células, la genómica funcional, la proteómica, la metabolómica y la regulación de los rasgos en organismos transgénicos, donde el control de gen los niveles de expresión es deseable. Reivindicación 1: Un compuesto que tiene la fórmula (1), donde: R¹ y R² se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, alquilo opcionalmente sustituido y haloalquilo; o R¹ y R² tomados en conjunto con el átomo de carbono al cual están unidos forman un cicloalquilo de 4 a 8 miembros; R³ se selecciona del grupo que consiste de hidrógeno, alquilo opcionalmente sustituido, haloalquilo, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R⁴ se selecciona del grupo que consiste de los restos del grupo de fórmulas (2); X¹ se selecciona del grupo que consiste de -O- y -N(R⁸ᵃ)-; Y¹ es -(CR⁹ᵃR⁹ᵇ)ₘ-; Z¹ se selecciona del grupo que consiste de -O- y -N(R⁸ᵇ)- o Z¹ está ausente; R⁶ᵃ se selecciona del grupo que consiste de hidroxi, alquilo y alcoxi; o R⁶ᵃ forma un aducto de hidroxi ácido o un aducto de amino ácido; R⁷ᵃ y R⁷ᵇ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, alcoxi y alquiltio; R⁷ᵃ y R⁷ᵇ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, alcoxi y alquiltio; R⁸ᵃ y R⁸ᵇ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; R⁹ᵃ y R⁹ᵇ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; m es 1, 2, 3 ó 4; X² se selecciona del grupo que consiste de -O- y -N(R⁸ᶜ)-; Y² es -(CR⁹ᶜR⁹ᵈ)ₙ-; Z² se selecciona del grupo que consiste de -O- y -N(R⁸ᵈ)- o Z² está ausente; R⁶ᵇ se selecciona del grupo que consiste de hidroxi, alquilo y alcoxi; o R⁶ᵇ forma un aducto de hidroxi ácido o un aducto de amino ácido; R⁷ᶜ y R⁷ᵈ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, alcoxi y alquiltio; R⁸ᶜ y R⁸ᵈ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; R⁹ᶜ y R⁹ᵈ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; n es 1, 2, 3 ó 4; X se selecciona del grupo que consiste de -O- y -N(R⁸ᵉ)-; R⁶ᶜ se selecciona del grupo que consiste de hidroxi, alquilo y alcoxi; o R⁶ᶜ forma un aducto de hidroxi ácido o un aducto de amino ácido; R⁷ᵉ y R⁷ᶠ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, alcoxi y alquiltio; R⁸ᵉ se selecciona del grupo que consiste de hidrógeno y alquilo; R⁶ᵈ se selecciona del grupo que consiste de hidroxi, alquilo y alcoxi; o R⁶ᵈ forma un aducto de hidroxi ácido o un aducto de amino ácido; R⁶ᶠ se selecciona del grupo que consiste de hidrógeno, alquilo, amino e hidroxi; X⁵ se selecciona del grupo que consiste de -O- y -N(R⁸ᵏ)-; R⁷ᵍ y R⁷ʰ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, alcoxi y alquiltio; R⁸ᵏ se selecciona del grupo que consiste de hidrógeno y alquilo; X⁶ se selecciona del grupo que consiste de -O- y -N(R⁸ˡ)-; X⁷ se selecciona del grupo que consiste de -O- y -N(R⁸ⁿ)-; R⁸ˡ se selecciona del grupo que consiste de hidrógeno y alquilo; R⁸ᵐ se selecciona del grupo que consiste de hidrógeno y alquilo; R⁸ⁿ se selecciona del grupo que consiste de hidrógeno y alquilo; R¹⁰ᵃ se selecciona del grupo que consiste de hidrógeno y -(CR¹¹ᵃR¹¹ᵇ)ₒ-B(R¹²ᵃ)(R¹²ᵇ); y R¹⁰ᵇ, R¹⁰ᶜ, y R¹⁰ᵈ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, -N(H)CHO, -N(H)CN, alquilo opcionalmente sustituido, haloalquilo, alcoxialquilo, hidroxialquilo, arilalquilo, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclo opcionalmente sustituido, alcoxi, ariloxi, arilalquiloxi, alquiltio, heteroalquilo, carboxamido, sulfonamido, -COR¹⁶, -SO₂R¹⁷, -N(R¹⁸)COR¹⁹, -N(R¹⁸)SO₂R²⁰ o N(R¹⁸)C=N(R²¹)-amino; o R¹⁰ᵇ se selecciona del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, -N(H)CHO, -N(H)CN, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, arilalquilo, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclo opcionalmente sustituido, alcoxi, ariloxi, arilalquiloxi, alquiltio, heteroalquilo, carboxamido, sulfonamido, -COR¹⁶, -SO₂R¹⁷, -N(R¹⁸)COR¹⁹, -N(R¹⁸)SO₂R²⁰ o -N(R¹⁸)C=N(R²¹)-amino; o R¹⁰ᶜ y R¹⁰ᵈ tomados en conjunto con dos átomos de carbono adyacentes forman un grupo cicloalquilo opcionalmente sustituido fusionado, heterociclo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R¹¹ᵃ y R¹¹ᵇ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; R¹²ᵃ y R¹²ᵇ se seleccionan del grupo que consiste de hidroxi y alcoxi; o R¹²ᵃ y R¹²ᵇ tomados en conjunto forman una unión -O(CR¹³ᵃR¹³ᵇ)ₚO-; o -B(R¹²ᵃ)(R¹²ᵇ) forma un aducto de flúor; R¹³ᵃ y R¹³ᵇ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo C₁₋₄; o es 0, 1, 2, 3, 4 ó 5; p es 2, 3 ó 4; R⁵ es un resto R⁴-3, R⁴-4, R⁴-8, R⁴-9 o R⁴-10 del grupo de fórmulas (2); o R⁵ se selecciona del grupo que consiste de los compuestos del grupo de fórmulas (3); X³ se selecciona del grupo que consiste de -O- y -N(R⁸ᶠ)-; Y³ es -(CR⁹ᵉR⁹ᶠ)q-; Z³ se selecciona del grupo que consiste de -O- y -N(R⁸ᵍ)- o Z³ está ausente; R⁶ᵉ se selecciona del grupo que consiste de hidroxi y alquilo; o R⁶ᵉ forma un aducto de hidroxi ácido o un aducto de amino ácido; R⁷ⁱ y R⁷ʲ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, alcoxi y alquiltio; R⁸ᶠ y R⁸ᵍ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; R⁹ᵉ y R⁹ᶠ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; q es 1, 2, 3 ó 4; X⁴ se selecciona del grupo que consiste de -O- y -N(R⁸ʰ)-; Y⁴ es -(CR⁹ᵍR⁹ʰ)ʳ-; Z⁴ se selecciona del grupo que consiste de -O- y -N(R⁸ⁱ)- o Z⁴ está ausente; R⁶ᵍ se selecciona del grupo que consiste de hidroxi y alquilo; o R⁶ᵍ forma un aducto de hidroxi ácido o un aducto de amino ácido; R⁷ᵏ y R⁷ˡ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, alcoxi y alquiltio; R⁸ʰ y R⁸ⁱ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; R⁹ᵍ y R⁹ʰ se seleccionan -cada uno en forma independiente- del grupo que consiste de hidrógeno y alquilo; r es 1, 2, 3 ó 4; R¹⁰ᵉ se selecciona del grupo que consiste de hidrógeno y -(CR¹¹ᶜR¹¹ᵈ)ₛ-B(R¹²ᶜ)(R¹²ᵈ); y R¹⁰ᶠ, R¹⁰ᵍ, y R¹⁰ʰ se seleccionan -de manera independiente- del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, -N(H)CHO, -N(H)CN, alquilo opcionalmente sustituido, haloalquilo, hidroxialquilo, arilalquilo, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclo opcionalmente sustituido, alcoxi, ariloxi, arilalquiloxi, alquiltio, carboxamido, sulfonamido, -COR¹⁶, -SO₂R¹⁷, -N(R¹⁸)COR¹⁹, -N(R¹⁸)SO₂R²⁰ o -N(R¹⁸)C=N(R²¹)-amino; o R¹⁰ᶠ se selecciona del grupo que consiste de hidrógeno, halo, nitro, ciano, hidroxi, amino, -N(H)CHO, -N(H)CN, alqu
ARP140101226A 2013-03-15 2014-03-17 Diazilhidrazinas que contienen boro AR095601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792412P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095601A1 true AR095601A1 (es) 2015-10-28

Family

ID=51529908

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101226A AR095601A1 (es) 2013-03-15 2014-03-17 Diazilhidrazinas que contienen boro

Country Status (21)

Country Link
US (4) US9127024B2 (es)
EP (1) EP2970106B1 (es)
JP (1) JP6379173B2 (es)
KR (1) KR20150129034A (es)
CN (1) CN105283439B (es)
AR (1) AR095601A1 (es)
AU (2) AU2014227571B2 (es)
BR (1) BR112015022994A2 (es)
CA (1) CA2904436C (es)
DK (1) DK2970106T3 (es)
ES (1) ES2683329T3 (es)
HK (1) HK1220441A1 (es)
IL (1) IL241119B (es)
MX (1) MX361717B (es)
NZ (1) NZ712167A (es)
PH (1) PH12015502099B1 (es)
RU (1) RU2637946C2 (es)
SG (1) SG11201506875YA (es)
TW (1) TWI636986B (es)
WO (1) WO2014144380A1 (es)
ZA (1) ZA201506985B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104307036A (zh) 2009-10-06 2015-01-28 明尼苏达大学董事会 一种微球形式的栓塞材料及其制备方法与栓塞悬浮液
HUE048859T2 (hu) 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
AU2014227571B2 (en) * 2013-03-15 2017-02-02 Intrexon Corporation Boron-containing diacylhydrazines
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
EP3194359B1 (en) * 2014-09-17 2020-04-08 Intrexon Corporation Boron-containing diacylhydrazine compounds
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105675559B (zh) * 2016-01-14 2018-01-30 中国科学院理化技术研究所 一种利用碳点作为荧光探针检测多巴胺的方法
TW201735792A (zh) 2016-03-07 2017-10-16 農業保鮮股份有限公司 使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法
US10182979B2 (en) 2016-03-22 2019-01-22 Regents Of The University Of Minnesota Biodegradable microspheres
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
PT3478693T (pt) 2016-06-30 2021-10-25 Qpex Biopharma Inc Derivados de ácido borónico e suas utilizações terapêuticas
KR102464380B1 (ko) * 2016-09-16 2022-11-07 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커
CA3039188A1 (en) * 2016-10-05 2018-04-12 The Global Alliance For Tb Drug Development, Inc. Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
CN109119689B (zh) * 2017-06-26 2020-11-20 比亚迪股份有限公司 非水电解液以及锂离子电池
BR112020005720A2 (pt) 2017-09-29 2020-10-20 Takeda Pharmaceutical Company Limited composto ou sal, medicamento, métodos para inibir monoacilglicerol lipase e para a profilaxia ou o tratamento de doença de alzheimer, doença de parkinson, doença de huntington, esclerose lateral amiotrófica, esclerose múltipla, distúrbio de ansiedade, dor, epilepsia ou depressão, e, uso do composto ou sal.
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN112592364A (zh) * 2020-12-22 2021-04-02 江西同和药业股份有限公司 一种克立硼罗中间、制备方法体及其在制备克立硼罗中的应用
WO2024163405A1 (en) * 2023-01-30 2024-08-08 5Metis, Inc. Boron containing compounds and their uses

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US5354762A (en) 1986-07-14 1994-10-11 Rohm And Haas Company Six-membered heterocyclic derivatives of N'-substituted N,N'-diacylhydrazines
DK483586A (da) * 1985-10-21 1987-04-22 Rohm & Haas Insecticide n'-substituerede-n,n'-diacylhydraziner
US5424333A (en) 1985-10-21 1995-06-13 Rohm And Haas Company Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
ES2027953T3 (es) 1985-12-09 1992-07-01 American Cyanamid Company Procedimiento para preparar una composicion insecticida.
US4814349A (en) 1985-12-09 1989-03-21 American Cyanamid Company Insecticidal substituted and unsubstituted benzoic acid 1-alkyl, 2 alkyl and 2-cycloalkylhydrazides
CA1338289C (en) 1986-01-22 1996-04-30 Raymond August Murphy Insecticidal n'-substituted-n-alkylcarbonyl- n'-acylhydrazines
CA1295618C (en) 1986-02-28 1992-02-11 Adam Chi-Tung Hsu Insecticidal n'-substituted-n-acyl -n'-alkylcarbonylhydrazines
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
CA1281716C (en) 1986-05-01 1991-03-19 Raymond August Murphy Insecticidal n-substituted-n'-substituted-n,n'- diacylhydrazines
DE3774347D1 (de) 1986-07-14 1991-12-12 Rohm & Haas Sechsgliedrige heterocyclische derivate von n'-substituierten n,n'-diacylhydrazinen.
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
ES2022342B3 (es) 1987-04-15 1991-12-01 Rohm & Haas Hidrazinas n-(opcinalmente sustituidas)-n'-sustituidas-n, n'-disustituidas, insecticidas.
US4906280A (en) 1987-10-14 1990-03-06 Pennwalt Corporation Tertiary butylhydrazides as plant growth regulators
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5171671A (en) 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
US5429952A (en) 1988-02-02 1995-07-04 Biocode, Inc. Marking of products to establish identity and source
US5110986A (en) 1988-04-26 1992-05-05 Rohm And Haas Company Synthesis of n-t-alkyl-1,2-diacylhydrazines
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
SG50681A1 (en) 1988-06-13 1998-07-20 American Biogenetic Sciences Method for the production of monoclonal antibodies utilizing a germfree animal
NZ229536A (en) 1988-06-15 1992-05-26 Rohm & Haas N'-substituted-n'-substituted carbonyl-n-substituted carbonyl-hydrazines and pesticidal compositions
AU637573B2 (en) 1988-06-16 1993-06-03 Dow Agrosciences Llc Hydrazine derivatives for pharmaceutical use
JPH02207066A (ja) 1989-02-07 1990-08-16 Ishihara Sangyo Kaisha Ltd ヒドラジン系化合物、それらの製造方法及びそれらを含有する有害動物防除剤
US4950666A (en) 1989-03-30 1990-08-21 Fmc Corporation Difluoroalkane and difluoroalkenylalkane pesticides
US4954655A (en) 1989-03-31 1990-09-04 Rohm And Haas Company Preparation of alkylhydrazines
EP0395581A1 (de) 1989-04-27 1990-10-31 Ciba-Geigy Ag N-Sulfenyl- und N-sulfinyl-N,N'-diacylhydrazide
NZ228936A (en) 1989-05-01 1992-04-28 Rohm & Haas Method for treating insect infestation in rice plants comprising applying diacylhydrazine derivatives
JPH03141245A (ja) 1989-10-24 1991-06-17 Ishihara Sangyo Kaisha Ltd ヒドラジン系化合物、それらの製造方法及びそれらを含有する有害動物防除剤
JPH03145447A (ja) 1989-10-31 1991-06-20 Nissan Chem Ind Ltd ジベンゾイルヒドラジン化合物および殺虫剤
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
ATE196310T1 (de) 1990-02-09 2000-09-15 Salk Inst For Biological Studi Retinoid-rezeptor-zusammensetzungen und verfahren
ES2180529T3 (es) 1990-02-26 2003-02-16 Univ Leland Stanford Junior Identificacion y expresion de secuencias de adn de un receptor de esteroides de insectos.
US7119077B1 (en) 1990-03-22 2006-10-10 The Salk Institute For Biological Studies Multimeric forms of members of the steroid/thyroid superfamily of receptors with the ultraspiracle receptor
JPH11508121A (ja) 1990-03-22 1999-07-21 ザ ソーク インスティテュート フォア バイオロジカル スタディーズ 昆虫レチノイドレセプター組成物および方法
US5641652A (en) 1990-03-22 1997-06-24 The Salk Institute For Biological Studies Insect retinoid-like receptor compositions and methods
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CA2043775A1 (en) 1990-06-14 1991-12-15 Dat P. Le Dibenzoylakylcyanohydrazines
JPH0539252A (ja) 1990-08-01 1993-02-19 Nippon Kayaku Co Ltd N,N’−ジベンゾイル−tert−ブチルヒドラジン誘導体およびそれを有効成分とする殺虫組成物
JP2885902B2 (ja) 1990-08-01 1999-04-26 日本化薬株式会社 N’―tert―ブチル―N―ハロゲノメチルスルフェニル―N,N’―ジベンゾイルヒドラジン誘導体およびそれを有効成分とする殺虫組成物
JP3068846B2 (ja) 1990-08-01 2000-07-24 日本化薬株式会社 新規ヒドラジン誘導体およびそれを有効成分とする殺虫組成物
US5075471A (en) 1990-10-09 1991-12-24 Rohm And Haas Company Insecticidal ferrocenoyl acylhydrazines
JP3087854B2 (ja) 1991-01-09 2000-09-11 日本化薬株式会社 新規ヒドラジン誘導体及びそれを有効成分とする殺虫組成物
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US5668175A (en) 1991-08-23 1997-09-16 The Salk Institute For Biological Studies Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids
DE69232188T2 (de) 1991-08-23 2002-06-20 Ligand Pharmaceuticals, Inc. Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen
AU2579692A (en) 1991-09-17 1993-04-27 Salk Institute For Biological Studies, The Receptor of the thyroid/steroid hormone receptor superfamily
JPH07503609A (ja) 1991-12-06 1995-04-20 ザ ソールク インスチチュート フォア バイオロジカル スタディズ リセプターのステロイド/甲状腺スーパーファミリーのメンバーの多量体型
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5344958A (en) 1992-11-23 1994-09-06 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
JPH06172342A (ja) 1992-12-07 1994-06-21 Nippon Kayaku Co Ltd 新規ヒドラジン誘導体およびそれを有効成分とする殺虫組成物
JP3298954B2 (ja) 1992-12-16 2002-07-08 三共株式会社 新規n,n’−ジベンゾイルヒドラジン誘導体及び殺虫組成物
JP3394777B2 (ja) 1993-05-27 2003-04-07 セレクタイド コーポレーション 位相学的に分離された、コードされた固相ライブラリー
US5358966A (en) 1993-06-08 1994-10-25 Rohm And Haas Company Turfgrass insecticides
DE69406227T2 (de) 1993-08-19 1998-04-30 Rohm & Haas Die Herstellung von 1,2-Diacyl-2-(t-alkyl)-Hydrazinen
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5482962A (en) 1994-07-22 1996-01-09 Rohm And Haas Company Insecticidal N,N'-disubstituted-N-N'-diacylhydrazines
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
EP0809509A4 (en) 1995-01-13 2000-02-02 Salk Inst For Biological Studi ALLOSTERIC REGULATION OF NUCLEAR HORMONE RECEPTORS
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
JP3600298B2 (ja) 1995-02-27 2004-12-15 日本化薬株式会社 新規ヒドラジン誘導体およびそれを有効成分とする殺虫組成物
JPH08231529A (ja) 1995-02-27 1996-09-10 Nippon Kayaku Co Ltd ヒドラジン誘導体およびそれを有効成分とする殺虫組成物
CA2213340C (en) 1995-03-03 2011-07-26 Novartis Ag Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand
WO1996037609A1 (en) 1995-05-26 1996-11-28 Zeneca Limited A gene switch comprising an ecdysone receptor
JPH09100262A (ja) 1995-06-06 1997-04-15 Rohm & Haas Co N,N’−ジアシル−N’−t−アルキルヒドラジン化合物の製造方法
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
IL126418A0 (en) 1996-04-05 1999-05-09 Salk Inst For Biological Studi Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same
US6723531B2 (en) * 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6025483A (en) 1996-06-05 2000-02-15 The Regents Of The University Of California Maize and cauliflower apetalai gene products and nucleic acid molecules encoding same
US5919667A (en) 1996-06-20 1999-07-06 The Salk Institute For Biological Studies Modular assembly retroviral vectors and uses thereof
US5948406A (en) 1996-08-12 1999-09-07 Rohm And Haas Company Immunogens, antibodies formed therefrom, and coating antigens useful in a diacylhydrazine immunoassay method
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
CA2296093A1 (en) 1997-07-10 1999-01-21 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression
DE19837620A1 (de) 1997-08-22 1999-02-25 Novartis Ag Organische Verbindungen
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白
US6756491B2 (en) 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
AUPP135698A0 (en) 1998-01-15 1998-02-05 Commonwealth Scientific And Industrial Research Organisation Insectical modalities
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
JP2000026423A (ja) 1998-07-09 2000-01-25 Otsuka Chem Co Ltd イソニコチノイルヒドラジン誘導体及び該誘導体を有効成分として含有する害虫防除剤
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
EP0984009A1 (en) 1998-08-25 2000-03-08 Rohm And Haas Company Benzodioxincarboxylic acid hydrazides as insecticides
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US5989863A (en) 1998-10-14 1999-11-23 Incyte Pharmaceuticals, Inc. Human ankyrin family protein
CN1177813C (zh) 1999-09-06 2004-12-01 华东理工大学 1,2-烷(芳)酰基芳酰基肼类昆虫生长调节剂及制备和应用
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
AU2001241682A1 (en) 2000-02-24 2001-09-03 The Salk Institute For Biological Studies Gene expression system based on chimeric receptors
ATE338135T1 (de) 2000-03-22 2006-09-15 Rheogene Holdings Inc Induziertes genexpressionssystem basierend auf ecdysonrezeptoren
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US6576422B1 (en) 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
US8715959B2 (en) 2001-02-20 2014-05-06 Intrexon Corporation Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2392508T3 (es) 2001-02-20 2012-12-11 Intrexon Corporation Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso
MXPA03007493A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
WO2002066615A2 (en) 2001-02-20 2002-08-29 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CN1161325C (zh) 2001-03-26 2004-08-11 江苏省农药研究所 作为杀虫剂的二酰基肼类化合物及制备此种化合物的中间体以及它们的制备方法
US6761759B2 (en) 2001-03-30 2004-07-13 Seiko Epson Corporation Ink composition, ink jet recording method and recorded matter
US7919269B2 (en) 2001-09-26 2011-04-05 Intrexon Corporation Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
MXPA04002810A (es) 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos.
US20050228016A1 (en) 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
CA2689137C (en) * 2007-05-29 2017-05-02 Intrexon Corporation Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
AU2014227571B2 (en) * 2013-03-15 2017-02-02 Intrexon Corporation Boron-containing diacylhydrazines
EP3194359B1 (en) 2014-09-17 2020-04-08 Intrexon Corporation Boron-containing diacylhydrazine compounds

Also Published As

Publication number Publication date
HK1220441A1 (zh) 2017-05-05
US9512148B2 (en) 2016-12-06
ES2683329T3 (es) 2018-09-26
AU2017202580A1 (en) 2017-05-11
MX361717B (es) 2018-12-14
RU2637946C2 (ru) 2017-12-08
EP2970106A1 (en) 2016-01-20
PH12015502099A1 (en) 2016-01-18
CA2904436C (en) 2019-06-04
PH12015502099B1 (en) 2016-01-18
US20200157122A1 (en) 2020-05-21
JP6379173B2 (ja) 2018-08-22
US20180079759A1 (en) 2018-03-22
AU2014227571A1 (en) 2015-10-01
MX2015011515A (es) 2016-01-22
BR112015022994A2 (pt) 2017-11-14
TWI636986B (zh) 2018-10-01
US20140274954A1 (en) 2014-09-18
SG11201506875YA (en) 2015-09-29
RU2015138798A (ru) 2017-04-24
US10464951B2 (en) 2019-11-05
CN105283439B (zh) 2018-02-02
DK2970106T3 (en) 2018-08-13
US9127024B2 (en) 2015-09-08
NZ712167A (en) 2018-05-25
CN105283439A (zh) 2016-01-27
JP2016522158A (ja) 2016-07-28
AU2017202580B2 (en) 2018-10-18
EP2970106B1 (en) 2018-05-16
KR20150129034A (ko) 2015-11-18
US20150322092A1 (en) 2015-11-12
WO2014144380A8 (en) 2015-08-13
EP2970106A4 (en) 2016-11-09
US10851119B2 (en) 2020-12-01
ZA201506985B (en) 2016-12-21
IL241119B (en) 2018-06-28
IL241119A0 (en) 2015-11-30
TW201524986A (zh) 2015-07-01
AU2014227571B2 (en) 2017-02-02
WO2014144380A1 (en) 2014-09-18
CA2904436A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
AR095601A1 (es) Diazilhidrazinas que contienen boro
AR096757A1 (es) Inhibidores de bromodominios
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR089939A1 (es) COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
CY1118435T1 (el) Παραγωγο μορφολινο νουκλεϊνικου οξεος
AR089550A1 (es) Compuestos quimicos
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
CR20170066A (es) Compuestos aminopirimidinilo como inhibidires de jak
AR098908A1 (es) Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida
AR081369A1 (es) Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
AR092684A1 (es) Compuestos de sulfonamida sustituidos
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
JP2013541600A5 (es)
AR093057A1 (es) Inhibidores de la syk
JP2014526533A5 (es)
ES2721098T3 (es) Compuestos para cromatografía de afinidad
MX2021011971A (es) Proceso para preparar cicloserinas sustituidas.
AR092173A1 (es) Inhibidores de la syk
AR093128A1 (es) Inhibidores de la syk
EA201391721A1 (ru) Способ получения полиморфной формы i эторикоксиба
AR101222A1 (es) Derivados de piridona
AR104533A1 (es) Derivados de ácido ciclopropano carboxílico y sus usos como inhibidores de leucotrieno c₄ sintasa
AR088511A1 (es) Derivados heterociclicos como moduladores de trpv3

Legal Events

Date Code Title Description
FB Suspension of granting procedure